BioGraph 55
PrivateLast Round
Series B
Jun 1, 2024
Total Funding Raised
$20.1M
Company Overview
BioGraph 55 is a drug discovery company that develops novel B-cell therapies and drugs for autoimmunity and immuno-oncology using a proprietary spatial 'omics' platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioGraph 55 Comparables
Compare BioGraph 55 with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rondo Therapeutics | 78% | |
| Tizona Therapeutics | 71% | |
| Xencor, Inc. | 68% | |
BioGraph 55 Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 1, 2024 | ||||
| Series A | Mar 1, 2023 |
BioGraph 55 Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pathway Bioventures | Series B, Series A |
| Red Tree Venture Capital | Series B, Series A |
| Pfizer Ventures | Series B, Series A |
BioGraph 55 Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about BioGraph 55's valuation, stock price, and market status.